Advertisement

Prostate Cancer Screening in African-American Men

  • Aaron A. Laviana
  • Peter A. Reisz
  • Matthew J. Resnick
Chapter

Abstract

African-American men exhibit higher-risk prostate cancer and exhibit worse outcomes when compared to other racial and ethnic groups. There remain important knowledge gaps specifically surrounding the implications of this observed outcome disparity with respect to appropriateness and intensity of active surveillance in African-American men. Only approximately a tenth of the men in most active surveillance programs are African-American, yet the results are generalized as applying to all men equally. Nevertheless, because even “very low-risk” prostate cancer appears different pathologically and epidemiologically, African-American men must understand these risks when they elect management for prostate cancer. Most specifically, they must be aware that if they decide on active surveillance, aggressive cancer may be missed.

Keywords

Prostate cancer screening in African-Americans African-American men prostate cancer screening PSA in African-American men Prostate cancer racial disparity Race and prostate cancer screening 

References

  1. 1.
    Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M. Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA, editors. SEER Cancer Statistics Review, 1975–2011. Bethesda, MD: National Cancer Institute. http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER web site, April 2014.
  2. 2.
    Odedina FT, et al. Prostate cancer disparities in black men of African descent: a comparative literature review of prostate cancer burden among Black men in the United States, Caribbean, United Kingdom, and West Africa. Infect Agent Cancer. 2009;4:S2.PubMedPubMedCentralCrossRefGoogle Scholar
  3. 3.
    Sundi D, et al. African American men with very low-risk prostate cancer exhibit adverse oncologic outcomes after radical prostatectomy: should active surveillance still be an option for them? J Clin Oncol. 2013;31:2991–7.PubMedPubMedCentralCrossRefGoogle Scholar
  4. 4.
    Resnick MJ, Canter DJ, Guzzo TJ, et al. Does race affect postoperative outcomes in patients with low-risk prostate cancer who undergo radical prostatectomy? Urology. 2009;73:620–3.PubMedCrossRefGoogle Scholar
  5. 5.
    Powell IJ, Bock CH, Ruterbusch JJ, Sakr W. Evidence supports a faster growth rate and/or earlier transformation to clinically significant prostate cancer in black than in white American men, and influences racial progression and mortality disparity. J Urol. 2010;183:1792–6.PubMedCrossRefGoogle Scholar
  6. 6.
    Mahal BA, et al. Getting back to equal: the influence of insurance status on racial disparities in the treatment of African American men with high-risk prostate cancer. Urol Oncol. 2014;32:1285–91.PubMedCrossRefGoogle Scholar
  7. 7.
    Taksler GB, Keating NL, Cutler DM. Explaining racial differences in prostate cancer mortality. Cancer. 2012;118:4280–9.CrossRefPubMedGoogle Scholar
  8. 8.
    Cowen ME, Kattan MW, Miles BJ. A national survey of attitudes regarding participation in prostate carcinoma testing. Cancer. 1996;78:1952–7.PubMedCrossRefGoogle Scholar
  9. 9.
    Evans S, et al. Clinical presentation and initial management of black men and white men with prostate cancer in the United Kingdom: the PROCESS cohort study. Br J Cancer. 2010;102:249–54.PubMedCrossRefGoogle Scholar
  10. 10.
    Powell IJ, Vigneau FD, Bock CH, Ruterbusch J, Heilbrun LK. Reducing prostate cancer racial disparity: evidence for aggressive early prostate cancer PSA testing of African American men. Cancer Epidemiol Biomark Prev. 2014;23:1505–11.CrossRefGoogle Scholar
  11. 11.
    Carlsson S, Vickers AJ, Roobol M, Eastham J, Scardino P, Lilja H, Hugosson J. Prostate cancer screening: facts, statistics, and interpretation in response to the US Preventive Service Task Force review. J Clin Oncol. 2012;30:2581–4.PubMedPubMedCentralCrossRefGoogle Scholar
  12. 12.
    Preventive Services Task Force US. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012;157(2):120–34.CrossRefGoogle Scholar
  13. 13.
    Fleshner K, Carlsson SV, Roobol MJ. The effect of the USPSTF PSA screening recommendation on prostate cancer incidence patterns in the USA. Nat Rev Urol. 2017;14:26–37.PubMedCrossRefGoogle Scholar
  14. 14.
    Lee DJ, MAllin K, Graves A, Chang SS, et al. Recent changes in prostate cancer screening practices and epidemiology. J Urol. 2017;198(6):1230–40.PubMedCrossRefGoogle Scholar
  15. 15.
    Buzzoni C, et al. Metastatic prostate cancer incidence and prostate-specific antigen testing: new insights from the European randomized study of screening for prostate cancer. Eur Urol. 2015;68:885–90.PubMedPubMedCentralCrossRefGoogle Scholar
  16. 16.
    Schroder FH, et al. The European randomized study of screening for prostate cancer—prostate cancer mortality at 13 years of follow-up. Lancet. 2014;382:2027–35.CrossRefGoogle Scholar
  17. 17.
    Murphy DG, Loeb S. Prostate cancer: growth of AS in the USA signals reduction in overtreatment. Nat Rev Urol. 2015;12:604–5.PubMedCrossRefGoogle Scholar
  18. 18.
    Bibbins-Domingo K, Grossman DC, Curry SJ. The US Preventive Service Task Force 2017 draft recommendation statement on screening for prostate cancer: an invitation to review and comment. JAMA. 2017;317:1949–50.PubMedCrossRefGoogle Scholar
  19. 19.
    Shenoy D, et al. Do African-American men need separate prostate cancer screening guidelines? BMC Urol. 2016;16:19.PubMedPubMedCentralCrossRefGoogle Scholar
  20. 20.
    Tangen CM, et al. Improved overall survival trends of men with newly diagnosed M1 prostate cancer: a SWOG phase III trial experience (S8494, S8894, & S9346). J Urol. 2012;188:1164–9.PubMedPubMedCentralCrossRefGoogle Scholar
  21. 21.
    Sarma AV, et al. Racial differences in longitudinal changes in serum prostate-specific antigen levels: the Olmsted County Study and the Flint Men’s Health Study. J Urol. 2014;83:88–93.CrossRefGoogle Scholar
  22. 22.
    McGreevy K, Rodgers K, Lipsitz S, Bissada N, Hoel D. Impact of race and baseline PSA on longitudinal PSA. Int J Cancer. 2006;118:1773–6.PubMedCrossRefGoogle Scholar
  23. 23.
    Henderson RJ, Eastham JA, Culkin DJ, Kattan MW, Whatley T, Mata J, Venable D, Sartor O. Prostate-specific antigen (PSA) and PSA density: racial differences in men without prostate cancer. J Natl Cancer Inst. 1997;89:134–8.PubMedCrossRefGoogle Scholar
  24. 24.
    Moul JW, et al. Prostate-specific antigen values at the time of prostate cancer diagnosis in African-American men. JAMA. 1995;274:1277–81.PubMedCrossRefGoogle Scholar
  25. 25.
    Mavropoulos JC, et al. Do racial differences in prostate size explain higher serum prostate-specific antigen concentrations among black men? Urology. 2007;69:1138–42.PubMedPubMedCentralCrossRefGoogle Scholar
  26. 26.
    Zhang W, Sesterhenn IA, Connelly RR, Mostofi FK, Moul JW. Inflammatory infiltrate (prostatitis) in whole mounted radical prostatectomy specimens from black and white patients is not an etiology for racial difference in prostate specific antigen. J Urol. 2000;163:131–6.PubMedCrossRefGoogle Scholar
  27. 27.
    Kubricht WS 3rd, Williams BJ, Whatley T, Pinckard P, Eastham JA. Serum testosterone levels in African-American and white men undergoing prostate biopsy. Urology. 1999;54:1035–8.PubMedCrossRefGoogle Scholar
  28. 28.
    Bensen JT, et al. Genetic polymorphism and prostate cancer aggressiveness: a case-only study of 1,536 GWAS and candidate SNPs in African-Americans and European-Americans. Prostate. 2013;73:11–22.PubMedCrossRefGoogle Scholar
  29. 29.
    Campbell MF, Wein AJ, Kavoussi LR, Partin AW, Peters CA, editors. Campbell-Walsh urology, Epidemiology, etiology, and prevention of prostate cancer. 11th ed. Philadelphia, PA: WB Saunders; 2016. p. 2546.Google Scholar
  30. 30.
    Goldgar DE, Easton DF, Cannon-Albright LA, Skolnick MH. Systematic population-based assessment of cancer risk in first-degree relatives of cancer probands. J Natl Cancer Inst. 1994;81:1600–8.CrossRefGoogle Scholar
  31. 31.
    Lange EM. Male reproductive cancers: epidemiology, pathology, and genetics. In: Foulkes WD, Cooney KA, editors. . New York: Springer; 2010. p. 203–28.CrossRefGoogle Scholar
  32. 32.
    Lichtenstein P, et al. Environmental and heritable factors in the causation of cancer—analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med. 2000;343:78–85.PubMedCrossRefGoogle Scholar
  33. 33.
    Lin DW, et al. Genetics variants in the LEPR, CRY1, RNASEL, IL4, and ARVCF genes are prognostic markers of prostate cancer-specific mortality. Cancer Epidemiol Biomark Prev. 2011;20:1928–36.CrossRefGoogle Scholar
  34. 34.
    Cooney KA, et al. Prostate cancer susceptibility locus on chromosome 1q: a confirmatory study. J Natl Cancer Inst. 1997;89:955–9.PubMedCrossRefGoogle Scholar
  35. 35.
    Ewing CM, et al. Germline mutations in HOVB13 and prostate-cancer risk. N Engl J Med. 2012;366:141–9.PubMedPubMedCentralCrossRefGoogle Scholar
  36. 36.
    Witte JS, et al. HOXB13 mutation and prostate cancer: studies of siblings and aggressive disease. Cancer Epidemiol Biomark Prev. 2013;22:675–80.CrossRefGoogle Scholar
  37. 37.
    Eeles R, et al. The genetic epidemiology of prostate cancer and its clinical implications. Nat Rev Urol. 2014;11:18–31.PubMedCrossRefGoogle Scholar
  38. 38.
    Castro E, et al. Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. J Clin Oncol. 2013;31:1748–57.PubMedPubMedCentralCrossRefGoogle Scholar
  39. 39.
    Cooney KA. Inherited predisposition to prostate cancer: from gene discovery to clinical impact. Trans Am Clin Climatol Assoc. 2017;128:14–23.PubMedPubMedCentralGoogle Scholar
  40. 40.
    Zheng SL, et al. Cumulative association of five genetic variants with prostate cancer. N Engl J Med. 2008;358:910.PubMedCrossRefGoogle Scholar
  41. 41.
    Powell IJ, et al. Genes associated with prostate cancer are differentially expressed in African American and European American men. Cancer Epidemiol Biomark Prev. 2013;22:891–7.CrossRefGoogle Scholar
  42. 42.
    Yamoah K, et al. Novel biomarker signature that may predict aggressive disease in African-American men with prostate cancer. J Clin Oncol. 2015;33:2789–96.PubMedPubMedCentralCrossRefGoogle Scholar
  43. 43.
    Tomlins SA, et al. Characterization of 1577 primary prostate cancers reveals novel biological and clinic opathologic insights into molecular subtypes. Eur Urol. 2015;68:555–67.PubMedPubMedCentralCrossRefGoogle Scholar
  44. 44.
    Haiman CA, et al. Genome-wide association study of prostate cancer in men of African ancestry identifies a susceptibility locus at 17q21. Nat Genet. 2011;43:570–3.PubMedPubMedCentralCrossRefGoogle Scholar
  45. 45.
    Freedman ML, et al. Admixture mapping identifies 8q24 as a prostate cancer risk locus in African-American men. Proc Natl Acad Sci U S A. 2006;103:14068–73.PubMedPubMedCentralCrossRefGoogle Scholar
  46. 46.
    Faisal FA, et al. Racial variations in prostate cancer molecular subtypes and androgen receptor signaling reflect anatomic tumor location. Eur Urol. 2016;70:14–7.CrossRefPubMedGoogle Scholar
  47. 47.
    Sundi D, et al. Pathological examination of radical prostatectomy specimens in men with very low risk disease at biopsy reveals distinct zonal distribution of cancer in black American men. J Urol. 2014;191:60–7.CrossRefPubMedGoogle Scholar
  48. 48.
    Tiguert R, Kabbani W, Sakr W, Gheiler EL, Pontes JE. Origin and racial distribution of glandular tissue in the anterior compartment of the prostate: an autopsy study. Prostate. 1999;39:310–5.PubMedCrossRefGoogle Scholar
  49. 49.
    Pettaway CA, et al. Prostate specific antigen and pathological features of prostate cancer in black and white patients: a comparative study based on radical prostatectomy specimens. J Urol. 1998;160:437–42.PubMedCrossRefGoogle Scholar
  50. 50.
    Beilin J, Ball EM, Favaloro JM, Zajac JD. Effect of the androgen receptor CAG repeat polymorphism on transcriptional activity: specificity in prostate and non-prostate cell lines. J Mol Endocrinol. 2000;25:85–96.PubMedCrossRefGoogle Scholar
  51. 51.
    Giovannucci E, et al. The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc Natl Acad Sci U S A. 1997;94:3320–3.PubMedPubMedCentralCrossRefGoogle Scholar
  52. 52.
    Bennett CL, et al. Racial variation in CAG repeat lengths within the androgen receptor gene among prostate cancer patients of lower socioeconomic status. J Clin Oncol. 2002;20:3599–604.PubMedCrossRefGoogle Scholar
  53. 53.
    Price DK, et al. Androgen receptor CAG repeat length and association with prostate cancer risk: results from the prostate cancer prevention trial. J Urol. 2010;184:2297–302.PubMedPubMedCentralCrossRefGoogle Scholar
  54. 54.
    Gilligan T, et al. Absence of a correlation of androgen receptor gene CAG repeat length and prostate cancer risk in an African-American population. Clin Prostate Cancer. 2004;3:98–103.PubMedCrossRefGoogle Scholar
  55. 55.
    Freedman ML, et al. Systematic evaluation of genetic variation at the androgen receptor locus and risk of prostate cancer in a multiethnic cohort study. Am J Hum Genet. 2005;76:82–90.PubMedCrossRefGoogle Scholar
  56. 56.
    Gaston KE, et al. Racial differences in androgen receptor protein expression in men with clinically localized prostate cancer. J Urol. 2003;170:990–3.PubMedCrossRefGoogle Scholar
  57. 57.
    de la Calle C, Patil D, Wei JT, et al. Multicenter evaluation of the prostate health index to detect aggressive prostate cancer in biopsy naive men. J Urol. 2015;194:65–72.PubMedPubMedCentralCrossRefGoogle Scholar
  58. 58.
    Loeb S, Sanda MG, Broyles DL, et al. The prostate health index selectively identifies clinically significant prostate cancer. J Urol. 2015;193:1163–9.PubMedCrossRefGoogle Scholar
  59. 59.
    Schwen ZR, Tosioan JJ, Sokoll LJ, et al. Prostate health index (PHI) predicts high-stage pathology in African American men. J Urol. 2016;90:136–40.CrossRefGoogle Scholar
  60. 60.
    Vickers AJ, Gupta A, Savage CJ, et al. A panel of kallikrein marker predicts prostate cancer in a large, population-based cohort followed for 15 years without screening. Cancer Epidemiol Biomark Prev. 2011;20:255–61.CrossRefGoogle Scholar
  61. 61.
    Nordstrom T, Vickers A, Assel M, Lilja H, Gronberg H, Eklund M. Comparison between the four-kallikrein panel and prostate health index for predicting prostate cancer. Eur Urol. 2015;68:139–44.PubMedCrossRefGoogle Scholar
  62. 62.
    Russo GI, Regis F, Castelli T, et al. A systematic review and meta-analysis of the diagnostic accuracy of prostate health index and 4-Kallikrein panel score in predicting overall and high-grade prostate cancer. Clin genitour. Cancer. 2016;15:429–39.Google Scholar
  63. 63.
    Van Neste L, Hendriks RJ, Dijkstra S, et al. Detection of high-grade prostate cancer using a urinary molecular biomarker-based risk score. Eur Urol. 2016;70:740–8.PubMedCrossRefGoogle Scholar
  64. 64.
    O’Malley PG, et al. Racial variation in the utility of urinary biomarkers PCA3 and T2ERG in a large multicenter study. J Urol. 2017;198:42–9.PubMedCrossRefPubMedCentralGoogle Scholar
  65. 65.
    Schoots IG, Roobol MJ, Nieboer D, et al. Magnetic resonance imaging-targeted biopsy may enhance the diagnostic accuracy of significant prostate cancer detection compared to standard transrectal ultrasound-guided biopsy: a systematic review and meta-analysis. Eur Urol. 2015;68:438–50.PubMedCrossRefGoogle Scholar
  66. 66.
    Shin T, et al. Detection of prostate cancer using magnetic resonance imaging/ultrasonography image-fusion targeted biopsy in African-American men. BJU Int. 2017;120:233–8.PubMedCrossRefGoogle Scholar
  67. 67.
    El-Shater Bosaily A, Parker C, Borwn LC, et al. PROMIS: prostate MR imaging study: a paired validating cohort study evaluating the role of multi-parametirc MRI in men with clinical suspicion of prostate cancer. Contemp Clin Trials. 2015;42:26–40.PubMedPubMedCentralCrossRefGoogle Scholar
  68. 68.
    Grenabo Bergdahl A, Wilderang U, Aus G, et al. Role of magnetic resonance imaging in prostate cancer screening: a pilot study within the Goteborg Randomised Screening Trial. Eur Urol. 2016;70:566–73.PubMedCrossRefGoogle Scholar
  69. 69.
    Kongnyuy M, et al. The significance of anterior prostate lesions on multiparametric magnetic resonance imaging in African-American men. Urol Oncol. 2016;34:254.PubMedCrossRefGoogle Scholar
  70. 70.
    Smith ZL, Eggener SE, Murphy AB. African-American prostate cancer disparities. Curr Urol Reports. 2017;18:81.CrossRefGoogle Scholar
  71. 71.
    Carroll, PR, Parsons JK, Andriole, G, et al. NCCN Clinical Practice Guidelines Prostate Cancer Early Detection, Version 2.2017. www.nccn.org/professionals/physician_gls/pdf/prostate.pdf.
  72. 72.
    Eastham JA, Riedel E, Scardino PT, et al. Variation of serum prostate-specific antigen levels: an evaluation of year-to-year fluctuations. JAMA. 2003;289:2695–700.PubMedCrossRefGoogle Scholar
  73. 73.
    Nordstrom T, Adolfsson J, Gronberg H, Eklund M. Repeat prostate-specific antigen tests before prostate biopsy decisions. J Natl Cancer Inst. 2016;108(12):djw165.PubMedCrossRefGoogle Scholar
  74. 74.
    Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level ≤ 4.0 ng per milliliter. N Engl J Med. 2004;350:2239–46.PubMedCrossRefGoogle Scholar
  75. 75.
    Loeb S, Roehl KA, Antenor JV, et al. Baseline prostate-specific antigen compared with median prostate-specific antigen for age group as predictor of prostate cancer risk in men younger than 60 years. Urology. 2006;67:316–20.PubMedCrossRefGoogle Scholar
  76. 76.
    Kryvenko ON, Balise R, Soodana Prakash N, Epstein JI. African-American men with Gleason score 3+3=6 prostate cancer produce less prostate specific antigen than Caucasian men: a potential impact on active surveillance. J Urol. 2016;195:301–6.PubMedCrossRefGoogle Scholar
  77. 77.
    Thompson IM, Ankerst DP, Chi C, et al. Assessing prostate cancer risk: results from the prostate cancer prevention trial. J Natl Cancer Inst. 2006;98:529–34.PubMedCrossRefGoogle Scholar
  78. 78.
    Kaplan DJ, Boorjian SA, Ruth K, et al. Evaluation of the prostate cancer prevention trial risk calculator in a high-risk screening population. BJU Int. 2010;105:334–7.PubMedCrossRefGoogle Scholar
  79. 79.
    Stanford JL, Stephenson RA, Coyle LM, et al. Prostate Cancer Trends 1973–1995. SEER Program. National Institutes of Health Publication 99-4543. Bethesda, MD: National Cancer Institute; 1999.Google Scholar
  80. 80.
    Merrill RM, Brawley OW. Prostate cancer incidence and mortality rates among whites and black men. Epidemiology. 1997;8:126–31.PubMedCrossRefGoogle Scholar
  81. 81.
    Jepson C, Kessler LG, Portnoy B, Gibbs T. Black- white differences in cancer prevention knowledge and behavior. Am J Public Health. 1991;81:501–4.PubMedPubMedCentralCrossRefGoogle Scholar
  82. 82.
    National Center for Chronic Disease Prevention and Health Promotion. Chronic disease in minority populations. Atlanta, GA: Centers for Disease Control and Prevention; 1992.Google Scholar
  83. 83.
    Freeman VL, Durazo-Arvizu R, Keys L, et al. Racial differences in survival among men with prostate cancer and comorbidity at time of diagnosis. Am J Public Health. 2004;94(5):803–8.PubMedPubMedCentralCrossRefGoogle Scholar
  84. 84.
    Cohen JH, Schoenbach VJ, Kaufman JS, et al. Racial differences in clinical progression among Medicare recipients after treatment for localized prostate cancer (United States). Cancer Causes Control. 2006;17(6):803–11.PubMedCrossRefGoogle Scholar
  85. 85.
    Mahal BA, Aizer AA, Ziehr DR, et al. Trends in disparate treatment of African-American men with localize prostate cancer across National Comprehensive Cancer Network risk groups. Urology. 2014;84(2):386–92.PubMedCrossRefGoogle Scholar
  86. 86.
    Zeliadt SB, Potosky AL, Etzioni R, et al. Racial disparity in primary and adjuvant treatment for nonmetastatic prostate cancer: SEER-Medicare trends 1991 to 1999. Urology. 2004;64(6):1171–6.PubMedCrossRefGoogle Scholar
  87. 87.
    Mahal BA, Ziehr DR, Aizer AA, et al. Getting back to equal: the influence of insurance status of racial disparities in the treatment of African American men with high-risk prostate cancer. Urol Oncol. 2014;32(8):1895–1.CrossRefGoogle Scholar
  88. 88.
    Daskivich TJ, Kwan L, Dash A, Litwin MS. Racial parity in tumor burden, treatment choice and survival outcomes in men with prostate cancer in the VA healthcare system. Prostate Cancer Prostatic Dis. 2015;18:104–9.PubMedCrossRefGoogle Scholar
  89. 89.
    Cullen J, Kuo H-C, Chen Y, et al. Prostate cancer outcomes for African American and Caucasian patients undergoing radical prostatectomy. JCO. 2017;35(6_suppl):40.CrossRefGoogle Scholar
  90. 90.
    Yamoah K, Walker A, Spangler E, et al. African-American race is a predictor of seminal vesicle invasion following radical prostatectomy. Clin Genitourin Cancer. 2015;13(2):e65–72.PubMedCrossRefGoogle Scholar
  91. 91.
    Faisal FA, Sundi D, Cooper JL, et al. Racial disparities in oncologic outcomes after radical prostatectomy: long-term follow-up. Urology. 2014;84(6):1434–41.PubMedPubMedCentralCrossRefGoogle Scholar
  92. 92.
    Gökce MI, Sundi D, Schaeffer E, Pettaway C. Is active surveillance a suitable option for African American men with prostate cancer? A systemic literature review. Prostate Cancer Prostatic Dis. 2017;20(2):127–36.PubMedCrossRefGoogle Scholar
  93. 93.
    Tyson MD, Alvarez J, Koyama T, et al. Racial variation in patient-reported outcomes following treatment for localized prostate cancer: results from the CEASAR study. Eur Urol. 2017;72(2):307–14.PubMedCrossRefGoogle Scholar
  94. 94.
    Sanchez-Ortiz RF, Troncoso P, Babaian RJ, et al. African-American men with nonpalpable prostate cancer exhibit greater tumor volume than matched white men. Cancer. 2006;107(1):75–82.PubMedCrossRefGoogle Scholar
  95. 95.
    Barocas DA, Gray DT, Fowke JH. Racial variation in the quality of surgical care for prostate cancer. J Urol. 2012;188(4):1279–85.PubMedPubMedCentralCrossRefGoogle Scholar
  96. 96.
    Klabunde CN, Potosky AL, Harlan LC, Kramer BS. Trends and black/white differences in treatment for nonmetastatic prostate cancer. Med Care. 1998;36:1337–48.PubMedCrossRefGoogle Scholar
  97. 97.
    Nambudiri VE, Landrum MB, McNeil BJ, et al. Understanding variation in primary prostate cancer treatment within the Veterans Health Administration. Urology. 2012;79:537–45.PubMedCrossRefGoogle Scholar
  98. 98.
    Turner W. The index of the pelvic brim as a basis of classification. J Anat Physiol. 1885;20:125–43.PubMedPubMedCentralGoogle Scholar
  99. 99.
    Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of childhood and adult obesity in the United States, 2011–2012. JAMA. 2014;311:806–14.PubMedPubMedCentralCrossRefGoogle Scholar
  100. 100.
    Swords K, Wallen EM, Pruthi RS. The impact of race on prostate cancer detection and choice of treatment in men undergoing a contemporary extended biopsy approach. Urol Oncol. 2010;28:280–4.PubMedCrossRefGoogle Scholar
  101. 101.
    Ziehr DR, Mahal BA, Aizer AA, et al. Income inequality and treatment of African American men with high-risk prostate cancer. Urol Oncol. 2015;33:18.e7–18.e13.CrossRefGoogle Scholar
  102. 102.
    Yamoah K, Beecham K, Hegarty SE, et al. Early results of prostate cancer radiation therapy: an analysis with emphasis on research strategies to improve treatment delivery and outcomes. BMC Cancer. 2013;13:23.PubMedPubMedCentralCrossRefGoogle Scholar
  103. 103.
    Winkfield KM, Chen MH, Dosoretz DE, et al. Race and survival following brachytherapy-based treatment for men with localized or locally advanced adenocarcinoma of the prostate. Int J Radiat Oncol Biol Phys. 2011;81(4):e345–50.PubMedCrossRefGoogle Scholar
  104. 104.
    Lowrance WT, Elkin ED, Yee DS, et al. Locally advanced prostate cancer: a population-based study of treatment patterns. BJU Int. 2012;109:1309–14.PubMedCrossRefGoogle Scholar
  105. 105.
    Lu-Yao G, Moore DF, Oleynick J, et al. Use of hormonal therapy in men with metastatic prostate cancer. J Urol. 2006;176:526–31.PubMedCrossRefGoogle Scholar
  106. 106.
    Bergman J, Saigal CS, Lorenz KA, et al. Hospice use and high-intensity care in men dying of prostate cancer. Arch Intern Med. 2011;171(3):204–10.PubMedCrossRefGoogle Scholar
  107. 107.
    Temel JS, Greer JA, Muzikansky A, et al. Early palliative care ofr patients with metastatic non-small-cell lung cancer. NEJM. 2010;363(8):733–42.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Aaron A. Laviana
    • 1
  • Peter A. Reisz
    • 1
  • Matthew J. Resnick
    • 1
    • 2
    • 3
  1. 1.Department of Urologic SurgeryVanderbilt University Medical CenterNashvilleUSA
  2. 2.Department of Health PolicyVanderbilt University Medical CenterNashvilleUSA
  3. 3.Tennessee Valley VA Health Care SystemNashvilleUSA

Personalised recommendations